Xeljanz XR 11 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FQV7K
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,539
Award facts
- Contract value 100% obligated
- $18,538.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $18,538.96 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) with a firm fixed price and no set-aside designation. The award was executed on January 30, 2026, with an ultimate completion date of February 2, 2026. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99 billion vehicle running through December 31, 2031, that supports comprehensive pharmaceutical supply to military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, competes on a full and open basis for federal contracts and regularly fulfills medical procurement needs for military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver a wide range of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies. This particular delivery order for XELJANZ XR—a medication used to treat rheumatoid arthritis and other autoimmune conditions—reflects the company's ongoing role as a critical vendor in the Defense Logistics Agency's medical supply chain for supporting Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQV7K?
SPE2DR26FQV7K was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FQV7K worth?
The government has obligated $18,539 on SPE2DR26FQV7K.
Is contract SPE2DR26FQV7K an order under another contract?
Yes. SPE2DR26FQV7K is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQV7K competed?
The extent of competition for SPE2DR26FQV7K was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award